BioTech
-
Let’s set the table for this year’s meeting
This is the online edition of Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here to get it…
Read More » -
For longer-lasting obesity drugs, biotechs turn to gene silencing
Enticed by the immense market opened by GLP-1 weight loss drugs Wegovy and Zepbound, a handful of biotech companies are…
Read More » -
Cytokinetics sells Royalty Pharma a share of its heart drug for up to $575M
Cytokinetics, a drugmaker that is expected to soon launch a promising new heart therapy called aficamten, said Wednesday that it…
Read More » -
Biogen, Guardant, AstraZeneca, H5N1 vaccine
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your…
Read More » -
Biogen joins immunology wave with $1.15 billion acquisition of Hi-Bio
Biogen is joining the industry’s fervor over immune and inflammatory disease drug development with a new acquisition. The Cambridge, Mass.,…
Read More » -
At flashy new research hub, AstraZeneca lays out ambitious growth goals
CAMBRIDGE, England — On a bit of a roll, AstraZeneca on Tuesday laid out ambitious growth goals for the rest…
Read More » -
Eli Lilly, AstraZeneca, Bristol Meyers Squibb
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your…
Read More » -
AltruBio raises $225 million to develop ulcerative colitis drug
Checkpoint inhibitors, drugs that unleash the immune system, have turned into blockbuster therapies that have transformed outcomes for some patients…
Read More » -
GSK’s asthma push continues as drug succeeds in Phase 3 trials
A new asthma treatment that could be administered just once every six months has succeeded in two Phase 3 trials,…
Read More » -
Experts on separating hype from reality
Artificial intelligence is a rapidly improving technology. But its progress in drug development faces an increasingly urgent threat: An unending…
Read More »